Last reviewed · How we verify
HRS-5965 tablets；HRS-5965 capsules
HRS-5965, developed by Chengdu Suncadia Medicine Co., Ltd., is a small molecule drug currently in Phase 2 clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH). The drug has completed a Phase 1 trial comparing capsule and tablet formulations in healthy subjects. No FDA label is available, and the drug is not yet approved for any indication.
At a glance
| Generic name | HRS-5965 tablets；HRS-5965 capsules |
|---|---|
| Sponsor | Chengdu Suncadia Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: